LUND, SWEDEN--(Marketwire - November 02, 2011) -
During Teva's 3(rd) Quarter 2011 Results Conference Call
today, Teva's CEO Shlomo Yanai commented "Last week we held a meeting with
FDA to discuss the NDA for laquinimod. Following the meeting we now believe
it would be premature to file NDA at this time. The FDA has offered to work
us to determine the best design for conducting an additional trial".
Active Biotech AB (publ)
President & CEO
ABOUT ACTIVE BIOTECH
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or
pivotal phase are laquinimod, an orally administered small molecule with
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
prostate cancer as well as ANYARA for use in cancer targeted therapy,
of renal cell cancer. In addition, laquinimod is in Phase II development
Crohn's and Lupus. Further projects in clinical development comprise the
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and
for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 14:30 a.m. CET on November 2, 2011.
Information regarding Active Biotech?s candidate drug laquinimod:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE